Producer
Shiseido Company, Limited (Pharmaceutical Chemicals)
Japanese cosmetics and personal care company (TYO: 4911, HQ Minato, Tokyo; ~¥1.1T revenue; world's 5th-largest cosmetics company); Shiseido Professional Business Division produces pharmaceutical-grade hyaluronic acid with FDA Drug Master File documentation for ophthalmic and injectable applications. Shiseido (founded 1872 — originally as Japan's first Western-style pharmacy in the Ginza district of Tokyo) is primarily known as a premium cosmetics brand (Clé de Peau Beauté, NARS, Drunk Elephant), but its pharmaceutical-grade HA is a critical supply component for ophthalmic surgery. The same Shiseido that makes luxury skincare creams sold at $200 at Sephora also makes the pharmaceutical HA that surgeons inject into the eye during cataract operations to protect the corneal endothelium. Shiseido's 1872 founding makes it older than the Japanese Meiji Constitution (1889) and contemporary with the opening of Japan to Western trade — the original Tokyo pharmacy that became a global beauty empire also supplies ingredients for eye surgery.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Shiseido Company, Limited (Pharmaceutical Chemicals) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Shiseido Company, Limited (Pharmaceutical Chemicals) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Prestige Brands
55%Personal Care & Mass Beauty
25%Professional (Salon)
12%Pharmaceutical & Life Science
8%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Shiseido (TYO: 4911) is globally recognized as one of the world's premier luxury cosmetics companies — Clé de Peau Beauté, NARS, and Drunk Elephant are sold at Sephora and high-end department stores for $50-$400 per product. What ophthalmic surgeons and hospital procurement specialists know — and the beauty industry does not — is that the same Shiseido produces pharmaceutical-grade sodium hyaluronate used as a viscoelastic agent in cataract surgery, knee injection, and other surgical and injectable applications. The HA in a Shiseido luxury face serum and the HA that an ophthalmologist injects into the anterior chamber of an eye during cataract surgery to protect the corneal endothelium may both originate from Shiseido's pharmaceutical chemistry division. A luxury cosmetics brand founded as a Tokyo pharmacy in 1872 is simultaneously in the surgical supply chain for one of the world's most common surgical procedures (cataract extraction) — a connection that Sephora customers and ophthalmic surgeons would each be surprised to discover.
Shiseido Company, Limited ↗Origin2023
Shiseido was founded in 1872 by pharmacist Arinobu Fukuhara in the Ginza district of Tokyo — established as Japan's first Western-style pharmacy, dispensing Western medicines at a time when the Meiji Restoration was forcing Japan's rapid modernization. Fukuhara chose Ginza (then being rebuilt in Western brick style) for the pharmacy specifically to signal modernity and Western scientific legitimacy. The cosmetics business developed from the pharmacy as Fukuhara recognized that Japanese consumers wanted Western beauty products alongside Western medicines. Shiseido introduced Japan's first toothpaste (1888), first cosmetics counter at a pharmacy (1897), and first cosmetics brand with scientific validation messaging — a pharmaceutical lineage that informed Shiseido's pharmaceutical chemistry capabilities that eventually produced pharmaceutical-grade hyaluronic acid for surgical applications.
Shiseido Company, Limited ↗